Aktien
& Wertpapierkurse
powered by
GOYAX
Ad Hoc Releases
2012/2013
-
Mar 25, 2013
- SYGNIS announces Management Board changes
-
Mar 04, 2013
- SYGNIS Pharma AG secures further financial resources with shareholder loan
-
Dec 20, 2012
- SYGNIS announces the adaptation of its organisation to the new business activity
-
Oct 17, 2012
- SYGNIS Pharma AG announces changes in Management Board
-
Sep 24, 2012
- SYGNIS Pharma AG / Genetrix Life Sciences, A.B., and Genetrix, S.L., Granted Exemption from Mandatory Tender Offer to Shareholders of SYGNIS Pharma AG
-
Sep 06, 2012
- SYGNIS announces intended changes in the Supervisory Board
-
Jul 31, 2012
- SYGNIS Announces Prolongation of Standby Equity Distribution Agreement
-
Jul 18, 2012
- SYGNIS Announces Proposed Combination of Business with GENETRIX’ subsidiary X-Pol
2011/2012
-
Jun 29, 2012
- SYGNIS announces acquisition of a loan from BASF SE
-
Dec 15, 2011
- SYGNIS Pharma AG announces key results of its Phase II trial of AX200 for the treatment of Acute Ischemic Stroke
-
Aug 10, 2011
- SYGNIS Pharma AG successfully completes capital increase
-
Jul 20, 2011
- SYGNIS Pharma AG decides on increase in share capital
-
Jun 15, 2011
- SYGNIS Pharma AG secures further financial resources with shareholder loan
2010/2011
-
Oct 29, 2010
- SYGNIS Pharma AG announces strategic restructuring
-
Oct 28, 2010
- Dr. Alfred Bach resigns as CEO of SYGNIS Pharma AG
2009/2010
-
Oct 19, 2009
- SYGNIS secures up to € 10 Million through a 3 year Standby Equity Distribution Agreement with Yorkville
2008/2009
-
Nov 14, 2008
- SYGNIS Pharma AG receives mandatory offer of dievini Hopp BioTech holding GmbH & Co. KG
-
Oct 15, 2008
- SYGNIS Pharma AG Approves Capital Increase
-
Jun 08, 2008
- SYGNIS announces agreement on acquisition of Amnestix Inc.
2007/2008
-
Jul 22, 2007
- SYGNIS announces successful completion of the clinical IIa study for AX200 in stroke (AXIS)